-
Changchun High & New Technology Industries to Launch GenSci125 Phase I Trial in US
•
Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading Chinese pharmaceutical company, has announced the upcoming initiation of a Phase I clinical study for its investigational drug GenSci125 in the United States. The study is designed to evaluate the drug’s efficacy in luteal supplementation or replacement for…
-
Hengrui Medicine Receives NMPA Approval for Phase II Cervical Cancer Study
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study. The study will investigate the combination of its PD-L1 monoclonal antibody adebrelimab (SHR-1316) with concurrent chemotherapy for the treatment of locally…
-
Roche’s Tecentriq SC Receives European Nod as First Subcutaneous PD-(L)1 Therapy
•
Halozyme Therapeutics (NASDAQ: HALO) has announced that the European Commission (EC) has granted marketing authorization to Roche (SWX: ROG) for its anti-PD-L1 drug Tecentriq SC (atezolizumab). This subcutaneous formulation utilizes Halozyme’s proprietary hyaluronidase Enhanze (rHuPH20) and is now approved for the same indications as the original intravenous version of Roche’s…
-
Sino Biopharmaceutical Commences Phase III Trial for Semaglutide Biosimilar in China
•
Sino Biopharmaceutical Ltd (HKG: 1177), a leading Chinese pharmaceutical company, has announced the initiation of a Phase III clinical study for its semaglutide biosimilar in China. The study is assessing the drug as a potential treatment for type 2 diabetes. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by…
-
Ocumension Therapeutics Sells $56.66 Million Stake in EyePoint Pharmaceuticals
•
Ocumension Therapeutics (HKG: 1477), a specialist in the ophthalmology sector in China, has announced plans to sell 2,910,501 shares of EyePoint Pharmaceuticals Inc., (NASDAQ: EYPT), representing a 5.96% stake in the US company. The transaction is expected to generate proceeds of USD 56.66 million (HKD 443 million). EyePoint Pharmaceuticals, established…
-
Yifan Pharmaceutical Wins Nod for Generic Diazoxide Oral Suspension in China
•
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that it has received marketing approval from the National Medical Products for its generic version of German pharmaceutical giant Bayer’s diazoxide oral suspension. This signifies that the drug has successfully passed the generic quality consistency evaluation (GQCE) process…
-
China Medical System Holdings Secures Exclusive Rights to Promote Xihong Biopharma’s Aesthetic Fillers
•
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a licensing agreement with Jiangxi Xihong Biopharma Co., Ltd, granting CMS exclusive promotion, marketing, and commercialization rights for Xihong Biopharma’s injectable polycaprolactone microspheres filler and injectable hydroxyapatite microspheres filler in China mainland, Hong Kong, Macau, and Taiwan. Both Category III…
-
Wuhan EasyDiagnosis Biomedicine Partners with Ailex Technology Group for Global Glycated Hemoglobin Testing Market
•
Wuhan EasyDiagnosis Biomedicine Co., Ltd (SHE: 002932), a Chinese biomedicine company, has announced a strategic partnership with Ailex Technology Group Co., Ltd. The collaboration aims to combine the companies’ respective strengths in technology, product development, market reach, and management expertise to make inroads into the global glycated hemoglobin testing market.…
